Q-omics provides the consensus-scored LCE3E profile across patient tissues and cancer cell-line models. LCE3E expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LCE3E is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, LCE3E RNA expression shows 8,149 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, LUSC, and ESCA as cancer lineages where LCE3E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE3E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE3E survival associations across molecular data types. LCE3E RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE3E RNA expression–survival associations across cancer types. High LCE3E expression shows unfavorable associations in LUAD, BLCA, KICH, BRCA, MESO and COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LCE3E RNA expression.
This table summarizes LCE3E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LCE3E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE3E shows lower tumor expression in BLCA and higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher LCE3E RNA expression in tumor versus normal tissue (log2 FC = +2.034, t-test p < 0.001).
This table shows molecular features associated with LCE3E in patient tissues and cancer cell lines. In patient samples, LCE3E shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE3E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
